Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic

NicVAX(®), a nicotine vaccine (3’AmNic-rEPA), has been clinically evaluated to determine if higher antibody concentrations are associated with higher smoking abstinence rates and if doses and frequency of administration are associated with increased antibody response. This randomized, double-blinded...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Hatsukami, Dorothy K., Jorenby, Douglas E., Gonzales, David, Rigotti, Nancy A., Glover, Elbert D., Oncken, Cheryl A., Tashkin, Donald P., Reus, Victor I., Akhavain, Roxanne C., Fahim, Raafat E.F., Kessler, Paul D., Niknian, Minoo, Kalnik, Matthew W., Rennard, Stephen I.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4106715/
https://ncbi.nlm.nih.gov/pubmed/21270788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/clpt.2010.317
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items